medigraphic.com
ISSN 0016-3813 (Print)

2015, Number 1

<< Back Next >>

Gac Med Mex 2015; 151 (1)

Miastenia gravis (MG) en adultos de instituciones pertenecientes al sistema público sanitario mexicano: un análisis de egresos hospitalarios durante el año 2010

Tolosa-Tort P, Chiquete E, Domínguez-Moreno R, Vega-Boada F, Reyes-Melo I, Flores-Silva F, Sentíes-Madrid H, Estañol-Vidal B, García-Ramos G, Herrera-Hernández M, Ruiz-Sandoval JL, Cantú-Brito C

Language: Spanish
References: 29
Page: 47-53
PDF size: 85.30 Kb.


ABSTRACT

Introduction: Epidemiological studies on myasthenia gravis (MG) in Mexico is mainly derived from experiences in referral centers. Objective: To describe the epidemiological characteristics of hospital discharges during 2010 with the diagnosis of MG in adults hospitalized in the Mexican public health system. Methods: We consulted the database of hospital discharges during 2010 of the National Health Information System (Ministry of Health, IMSS, IMSS oportunidades, ISSSTE, PEMEX, and the Ministry of Defense). The MG records were identified by the code G70.0 of the International Classification of Diseases 10th revision. Results: During 2010 there were 5,314,132 hospital discharges (4,254,312 adults). Among them, 587 (0.01%) were adults with MG (median age: 47 years, 60% women). Women with MG were significantly younger than men (median age: 37 vs. 54 years, respectively; p ‹ 0.001). The median hospital stay was six days. The case fatality rate was 3.4%, without gender differences. Age was associated with the probability of death. Conclusions: We confirmed the bimodal age-gender distribution in MG. The in-hospital case fatality rate in Mexico is consistent with recent reports around the world.


REFERENCES

  1. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptors. Science. 1973;180:871-2.

  2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto- antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365-8.

  3. Berrih S, Morel E, Gaud C, Raimond F, LeBrigand H, Bach JF. Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis. Neurology. 1984;34:66-71.

  4. Phillips LH 2nd. The epidemiology of myasthenia gravis. Ann N Y Acad Sci. 2003;998:407-12.

  5. Phillips LH, Torner JC. Epidemiologic evidence for changing natural history of myasthenia gravis. Neurology. 1996;47:1233-8.

  6. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurology. 2010;10:46.

  7. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141-9.

  8. Zhang X, Yang M, Xu J, et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry. 2007;78:386-90.

  9. Trouth AJ, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia Gravis: A Review. Autoinmune Diseases. 2012;2012:1-10.

  10. Murthy JMK, Meena AK, Chowdary GVS, Naryanan JT. Myasthenic crisis: clinical features, complications and mortality. Neurology India. 2005;53:37-40.

  11. Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48:1253-60.

  12. Egresos hospitalarios SINAIS, México. [Internet]. Base de datos sobre egresos hospitalarios 2010. Consultado el 1 de junio de 2012. Disponible en: http://www.sinais.salud.gob.mx/basesdedatos/std_egresoshospitalarios. html.

  13. Echeverría-Galingo G, Mardueño-Ibarra MT, González-Jaime JJ, et al. Miastenia Gravis en un hospital del occidente de México. Rev Mex Neuroci. 2008;9:278-82.

  14. Navarro-Reynoso F, Pérez-Romo A, Green L, Páramo-Arroyo R, Cicero- Sabido R. Resultados de la timectomía máxima en miastenia gravis. Experiencia de 20 años en el Servicio de Neumología y Cirugía de Tórax en el Hospital General de México. Influencia de la timectomía en dosis de piridostigmina y tres variables espirométricas en miastenia gravis. Rev Inst Nal Enf Resp Mex. 2006;19:252-7.

  15. Remes-Troche JM, Téllez-Zenteno JF, Estañol B, Garduño-Espinoza J, García-ramos G. Thymectomy in miastheny gravis: response, complications and associated conditions. Arch Med Res. 2002;33:245-51.

  16. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009,8:475-90.

  17. Drachman DB. Myasthenia Gravis. New Engl J Med. 1994;330:1797-810.

  18. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009;72:1548-54.

  19. Christensen PB, Jensen TS, Tsiropoulos I, et al. Mortality and survival: a Danish population based study. J Neurol Neurosurg Psychiatry. 1998;64:78-83.

  20. Souayah N, Nasar A, Suri MFK, Kirmani JF, Ezzeddine MA, Qureshi AI. Trends in Outcomes and Hospitalization Charges among Mechanically Ventilated Patients with Myasthenia Gravis in the United States. Int J Biomed Sci. 2009;5:209-14.

  21. Broessner G, Helbok R, Lackner P, et al. Survival and long-term functional outcome in 1,155 consecutive neurocritical care patients. Crit Care Med. 2007;35:2025-30.

  22. Kiphuth C, Schellinger PD, Köhrmann M, et al. Predictors for good functional outcome after neurocritical care. Critical Care. 2010;14:R136.

  23. Sánchez-Barriga JJ. [Performance of ischemic heart disease mortality in Mexico in the period 2000-2007]. Gac Med Mex. 2009;145:375-82.

  24. Chiquete E, Ruiz-Sandoval JL, Murillo-Bonilla LM, et al. Mortalidad por enfermedad vascular cerebral en México, 2000-2008: Una exhortación a la acción. Rev Mex Neuroci. 2011;12:235-41.

  25. Sánchez-Barriga JJ. [Mortality trends from cervical cancer in the seven socioeconomic regions and the thirty two federative entities of Mexico, 2000-2008]. Gac Med Mex. 2012;148:42-51.

  26. Chiquete E, Ruíz-Sandoval JL, Murillo-Bonilla LM, et al. Egresos por enfermedad vascular cerebral aguda en instituciones públicas del sector salud de México: Un análisis de 5.3 millones de hospitalizaciones en 2010. Rev Mex Neuroci. 2012;13:252-8.

  27. Rodríguez Hernández JM, González Nájera R, Albavera Hernández C. [Behavior of hypertensive renal diseases in Mexico between 1998-2009. A growing problem]. Gac Med Mex. 2013;149:152-60.

  28. Orozco-Valerio Mde J, Miranda-Altamirano RA, Méndez Magaña AC, Celis A. [Trends in mortality by burns in Mexico, 1979-2009]. Gac Med Mex. 2012;148:349-57.

  29. Kuri-Morales P, Chávez-Cortés C. [The system transformation and public health]. Gac Med Mex. 2012;148:509-17.




2020     |     www.medigraphic.com